Group 1 - The core viewpoint of the article is that Jefferies has raised its revenue and net profit forecasts for WuXi Biologics (02269) for the years 2025 to 2027, indicating a positive outlook for the company's growth [1] - Revenue forecast has been adjusted upwards by 0% to 4%, while net profit forecast has been increased by 0% to 7% [1] - The gross margin is expected to rise from 28.5% in 2024 to 30.8% in 2027 [1] Group 2 - Jefferies has raised the target price for WuXi Biologics from HKD 34.8 to HKD 42.6, maintaining an outperform rating [1] - The profitability and valuation of the Contract Research Organization (CRO) industry are sensitive to changes in the funding environment [1] - The potential interest rate cuts in the US in the second half of the year are expected to enhance market preference for the CRO sector [1] Group 3 - It is anticipated that global biotech companies will increase R&D investments in a more favorable funding environment from the second half of this year into next year [1] - Pharmaceutical companies are also expected to expand R&D spending to alleviate patent barrier pressures, which will continue to benefit WuXi Biologics [1]